Hepatitis E: Update on Prevention and Control.
Juliana Gil MelgaçoNoemi Rovaris GardinaliVinicius da Motta de MelloMariana LealLia Laura Lewis-XimenezMarcelo Alves PintoPublished in: BioMed research international (2018)
Hepatitis E virus (HEV) is a common etiology of acute viral hepatitis worldwide. Recombinant HEV vaccines have been developed, but only one is commercially available and licensed in China since 2011. Epidemiological studies have identified genotype 3 as the major cause of chronic infection in immunocompromised individuals. Ribavirin has been shown to be effective as a monotherapy to induce HEV clearance in chronic patients who have undergone solid organ transplant (SOT) under immunosuppressive therapy. Efforts and improvements in prevention and control have been made to reduce the instances of acute and chronic hepatitis E in endemic and nonendemic countries. However, this review shows that further studies are required to demonstrate the importance of preventive vaccination and treatment worldwide, with emphasis on hepatitis E infection in the public health system.
Keyphrases
- drug induced
- liver failure
- respiratory failure
- healthcare
- ejection fraction
- newly diagnosed
- randomized controlled trial
- mental health
- aortic dissection
- stem cells
- prognostic factors
- emergency department
- clinical trial
- case control
- intensive care unit
- mesenchymal stem cells
- bone marrow
- hepatitis b virus
- mechanical ventilation
- acute respiratory distress syndrome
- study protocol
- electronic health record